The Fondaparinux paradox: Fondaparinux-related heparin-induced thrombocytopenia

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Fondaparinux, a pentasaccharide administered for heparin-induced thrombocytopenia (HIT), can lead to the occurrence of thrombocytopenia. This patient underwent aortic stent graft placement for Salmonella paratyphi A-infected abdominal aortic aneurysm. Fondaparinux was administered for anticoagulation that led to a dramatic decline in his platelet counts. Investigations revealed HIT profile, PF4/heparin by particle gel immunoassay to be positive. Fondaparinux, a prescribed anticoagulant for HIT can paradoxically predispose to thrombocytopenia.

Cite

CITATION STYLE

APA

Vadi, S., & Peshattiwar, V. (2018). The Fondaparinux paradox: Fondaparinux-related heparin-induced thrombocytopenia. Indian Journal of Critical Care Medicine, 22(2), 116–118. https://doi.org/10.4103/ijccm.IJCCM_189_17

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free